Compound | Average ranking | Yes for DLB and PDD | Yes only for DLB | Yes only for PDD |
|---|
Ambroxol | 2.6 | 68% | | 11% |
Nilotinib/Bosutinib | 2.7 | 60% | 3% | 3% |
Liraglutide/Exenatide | 3.3 | 58% | 8% | 8% |
Metformin | 3.7 | 54% | 3% | 8% |
Candesartan/Telmisartan | 3.8 | 57% | 5% | 8% |
Fasudil | 4.0 | 61% | | 6% |
Etanercept | 5.4 | 38% | 3% | 3% |
Rasagiline | 5.6 | 27% | | 14% |
Salbutamol | 5.9 | 30% | | |
- The table provides the list of compounds prioritised by the Delphi consensus panel with the highest preference at the top. The consensus panel members were asked to nominate a list of up to ten compounds, rank them in order of preference and specify whether they believe the would be suitable for dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD) or both. Ranking ranged from 1 to 9. Please note that in the average ranking the lowest the score reflects the highest preference for the compound to be taken forwards
